PCDH17, protocadherin 17, 27253

N. diseases: 51; N. variants: 5
Source: ALL
Disease Score gda Association Type Type Original DB Sentence supporting the association PMID PMID Year
CUI: C0036341
Disease: Schizophrenia
Schizophrenia 		0.410 Biomarker disease PSYGENET Subsequent real-time PCR has shown that mRNA for muscleblind protein 1 (MBNL1) and protocadherin 17 (PCDH17) are increased in BA 46 from subjects with schizophrenia of short, but not long, duration. 17464717 2007
CUI: C0036341
Disease: Schizophrenia
Schizophrenia 		0.410 Biomarker disease BEFREE Subsequent real-time PCR has shown that mRNA for muscleblind protein 1 (MBNL1) and protocadherin 17 (PCDH17) are increased in BA 46 from subjects with schizophrenia of short, but not long, duration. 17464717 2007
CUI: C0027651
Disease: Neoplasms
Neoplasms 		0.100 PosttranslationalModification group BEFREE These results suggest that silencing of PCDH17 expression through hypermethylation of the promoter or other mechanisms leads to loss of its tumour-suppressive activity, which may be a factor in the carcinogenesis of a subgroup of ESCCs. 20200074 2010
CUI: C1269955
Disease: Tumor Cell Invasion
Tumor Cell Invasion 		0.040 AlteredExpression phenotype BEFREE Restoration of PCDH17 expression in ESCC cells reduced cell proliferation and migration/invasion. 20200074 2010
CUI: C0279626
Disease: Squamous cell carcinoma of esophagus
Squamous cell carcinoma of esophagus 		0.010 PosttranslationalModification disease BEFREE These results suggest that silencing of PCDH17 expression through hypermethylation of the promoter or other mechanisms leads to loss of its tumour-suppressive activity, which may be a factor in the carcinogenesis of a subgroup of ESCCs. 20200074 2010
CUI: C0596263
Disease: Carcinogenesis
Carcinogenesis 		0.010 PosttranslationalModification phenotype BEFREE These results suggest that silencing of PCDH17 expression through hypermethylation of the promoter or other mechanisms leads to loss of its tumour-suppressive activity, which may be a factor in the carcinogenesis of a subgroup of ESCCs. 20200074 2010
CUI: C0027651
Disease: Neoplasms
Neoplasms 		0.100 Biomarker group BEFREE High resolution ArrayCGH and expression profiling identifies PTPRD and PCDH17/PCH68 as tumor suppressor gene candidates in laryngeal squamous cell carcinoma. 21213369 2011
CUI: C0280324
Disease: Laryngeal Squamous Cell Carcinoma
Laryngeal Squamous Cell Carcinoma 		0.030 Biomarker disease BEFREE High resolution ArrayCGH and expression profiling identifies PTPRD and PCDH17/PCH68 as tumor suppressor gene candidates in laryngeal squamous cell carcinoma. 21213369 2011
CUI: C0005684
Disease: Malignant neoplasm of urinary bladder
Malignant neoplasm of urinary bladder 		0.050 PosttranslationalModification disease BEFREE PCDH17 and TCF21 methylation levels provided a sensitivity rate of 92% for bladder cancer, 67% for renal cell tumors and 96% for prostate cancer. 21847011 2011
CUI: C0005695
Disease: Bladder Neoplasm
Bladder Neoplasm 		0.050 PosttranslationalModification disease BEFREE PCDH17 and TCF21 methylation levels provided a sensitivity rate of 92% for bladder cancer, 67% for renal cell tumors and 96% for prostate cancer. 21847011 2011
CUI: C0699885
Disease: Carcinoma of bladder
Carcinoma of bladder 		0.050 PosttranslationalModification disease BEFREE PCDH17 and TCF21 methylation levels provided a sensitivity rate of 92% for bladder cancer, 67% for renal cell tumors and 96% for prostate cancer. 21847011 2011
CUI: C0751571
Disease: Cancer of Urinary Tract
Cancer of Urinary Tract 		0.010 Biomarker disease BEFREE TCF21 and PCDH17 methylation: An innovative panel of biomarkers for a simultaneous detection of urological cancers. 21847011 2011
CUI: C0027651
Disease: Neoplasms
Neoplasms 		0.100 Biomarker group BEFREE We focused on it as a candidate tumor suppressor gene (TSG) and hypothesized that PCDH17 may be susceptible to promoter methylation and gene silencing. 22207556 2012
CUI: C0006826
Disease: Malignant Neoplasms
Malignant Neoplasms 		0.030 AlteredExpression group BEFREE PCDH17 mRNA expression was down-regulated in cancer tissues, and PCDH17 promoter in cancer tissues was hyper-methylated in comparison with normal ones. 22207556 2012
CUI: C1306459
Disease: Primary malignant neoplasm
Primary malignant neoplasm 		0.030 AlteredExpression group BEFREE PCDH17 mRNA expression was down-regulated in cancer tissues, and PCDH17 promoter in cancer tissues was hyper-methylated in comparison with normal ones. 22207556 2012
CUI: C0024623
Disease: Malignant neoplasm of stomach
Malignant neoplasm of stomach 		0.010 AlteredExpression disease BEFREE PCDH17 mRNA expression in pairs of gastric cancer and normal tissue samples and cell lines were determined by quantitative real-time polymerase chain reaction. 22207556 2012
CUI: C0699791
Disease: Stomach Carcinoma
Stomach Carcinoma 		0.010 AlteredExpression disease BEFREE PCDH17 mRNA expression in pairs of gastric cancer and normal tissue samples and cell lines were determined by quantitative real-time polymerase chain reaction. 22207556 2012
CUI: C0027651
Disease: Neoplasms
Neoplasms 		0.100 Biomarker group BEFREE Thus, PCDH17 acts as a tumour suppressor, exerting its anti-proliferative activity through inducing apoptosis and autophagy, and is frequently silenced in gastric and colorectal cancers. 22926751 2013
CUI: C0686619
Disease: Secondary malignant neoplasm of lymph node
Secondary malignant neoplasm of lymph node 		0.040 AlteredExpression disease BEFREE PCDH17 protein expression was significantly correlated with low tumour stage and less lymph node metastasis of gastric and colorectal cancer patients, indicating its potential as a tumour marker. 22926751 2013
CUI: C0009402
Disease: Colorectal Carcinoma
Colorectal Carcinoma 		0.030 AlteredExpression disease BEFREE Thus, PCDH17 acts as a tumour suppressor, exerting its anti-proliferative activity through inducing apoptosis and autophagy, and is frequently silenced in gastric and colorectal cancers. 22926751 2013
CUI: C0005684
Disease: Malignant neoplasm of urinary bladder
Malignant neoplasm of urinary bladder 		0.050 PosttranslationalModification disease BEFREE PCDH17 promoter methylation was significantly associated with malignant behaviour and poor prognosis of bladder cancer. 24366498 2014
CUI: C0005695
Disease: Bladder Neoplasm
Bladder Neoplasm 		0.050 PosttranslationalModification disease BEFREE PCDH17 promoter methylation was significantly associated with malignant behaviour and poor prognosis of bladder cancer. 24366498 2014
CUI: C0699885
Disease: Carcinoma of bladder
Carcinoma of bladder 		0.050 PosttranslationalModification disease BEFREE PCDH17 promoter methylation was significantly associated with malignant behaviour and poor prognosis of bladder cancer. 24366498 2014
CUI: C0027651
Disease: Neoplasms
Neoplasms 		0.100 PosttranslationalModification group BEFREE Protocadherin 17 promoter methylation in tumour tissue from patients with bladder transitional cell carcinoma. 24567353 2014
CUI: C0005684
Disease: Malignant neoplasm of urinary bladder
Malignant neoplasm of urinary bladder 		0.050 PosttranslationalModification disease BEFREE PCDH17 promoter methylation is closely associated with bladder cancer malignancy and may be used as an independent predictor of clinical outcomes in patients with bladder cancer. 24567353 2014